Vitamin D Level Reference Tool

What 25-OH Vitamin D Measures

The test reported on a typical lab result measures 25-hydroxyvitamin D — often abbreviated as 25-OH-D or 25(OH)D, and also called calcidiol. Research suggests this is the principal storage form of vitamin D circulating in the bloodstream. The liver converts both the vitamin D3 produced in skin during sun exposure and the vitamin D absorbed from food or supplements into this compound. Because 25-OH-D has a biological half-life of approximately two to three weeks, studies indicate that a single blood draw provides a reasonable snapshot of recent cumulative vitamin D status rather than just reflecting recent days of intake or exposure.

The measurement differs from 1,25-dihydroxyvitamin D (calcitriol), the hormonally active form, which the kidneys produce on demand and which research suggests is tightly regulated regardless of stores. Testing calcitriol generally provides limited information about overall vitamin D reserves; 25-OH-D is the marker most commonly used for general assessment of vitamin D status.

Reference Ranges Across Major Guidelines

The table below summarises how major health organisations classify vitamin D status. Note that exact cutoffs vary; these are the commonly cited thresholds.

Why Guidelines Disagree

The divergence between the IOM 2010 and Endocrine Society 2011 recommendations reflects a difference in scope. The IOM approached vitamin D as a public health question: what level may cover the nutritional needs of 97.5% of the general healthy population for established outcomes — primarily bone mineralisation? Using randomised trial and dose-response data, they concluded that ≥20 ng/mL (50 nmol/L) was sufficient for this purpose. The Endocrine Society took a clinical lens, asking what threshold to use when evaluating individuals who might be at risk, and consensus thresholds typically suggested a more conservative target of ≥30 ng/mL (75 nmol/L). Both positions had internal logic for their stated purpose.

The 2024 Endocrine Society update represents a meaningful recalibration. After reviewing accumulating trial data — including large supplementation trials that largely failed to show benefit in vitamin D-replete populations — the guideline acknowledged that evidence for a single optimal target beyond bone-related outcomes in the general population remains insufficient. The update discouraged routine testing in asymptomatic adults without risk factors, pushing back against the widespread practice of population-level screening that grew from the 2011 guideline. Clinicians still use vitamin D assessment in specific contexts (e.g., malabsorption, chronic kidney disease, osteoporosis evaluation, pregnancy), but the era of universal optimal targets may be behind us.

Educational Context: Vitamin D Physiology and Bone Syndromes

Research on vitamin D physiology describes two well-known syndromes historically associated with severely low 25-OH-D levels: rickets in children, characterised by impaired bone mineralisation during growth, and osteomalacia in adults, where bone tissue may not mineralise properly even after skeletal maturity. These conditions are described in clinical literature in the context of pronounced, sustained vitamin D inadequacy combined with low calcium intake, and are uncommon in populations with adequate dietary intake or supplementation. The presence of any clinical concern of this kind should always be evaluated by a qualified healthcare provider.

Factors Commonly Associated With Low Vitamin D

Research suggests that lower 25-OH-D levels may be associated with multiple overlapping factors:

• Limited sun exposure: Studies indicate that living at high latitude (above approximately 37°N), winter months, indoor work, wearing full-coverage clothing, darker skin pigmentation (which research suggests reduces UVB-driven synthesis), and habitual sunscreen use may all reduce cutaneous vitamin D production.
• Low dietary intake: Few foods are naturally rich in vitamin D (fatty fish, egg yolks, liver). Fortified foods (milk, some cereals) contribute in some populations. Vegan diets without supplementation may be associated with lower intake.
• Malabsorption conditions: Research suggests that coeliac disease, inflammatory bowel disease (Crohn's, ulcerative colitis), and prior bariatric surgery may impair fat-soluble vitamin absorption, including vitamin D.
• Body composition: Vitamin D is fat-soluble and studies indicate it partitions into adipose tissue, which may reduce bioavailability in the circulation relative to body weight.
• Kidney and liver function: The liver converts vitamin D to 25-OH-D; the kidneys convert it to the active 1,25-OH form. Research suggests that disease in either organ may disrupt this pathway.
• Certain medications: Studies indicate that anticonvulsants (phenytoin, carbamazepine), rifampicin, and long-term glucocorticoids may accelerate the catabolism of vitamin D metabolites.

Seasonal and Supplementation Context

Research suggests that 25-OH-D levels often follow seasonal patterns in temperate latitudes, with values commonly trending lower during winter months when UVB exposure is reduced, and higher during summer months. Supplementation context varies widely by guideline: NHS / NICE guidance, for example, suggests considering vitamin D supplementation during October to March in the UK population, while the 2024 Endocrine Society update notes that evidence does not strongly support routine supplementation in otherwise healthy adults without established risk factors. Decisions about supplementation should always be discussed with a qualified healthcare provider.

Higher Vitamin D Values and Hypervitaminosis

Hypervitaminosis D (very high vitamin D) is described in the research literature as uncommon from food sources or moderate supplementation. Research suggests the primary mechanism is hypercalcaemia (elevated blood calcium), which has been associated with symptoms such as nausea, weakness, and effects on the kidneys and heart in case reports. Consensus thresholds typically suggest that sustained 25-OH-D values above approximately 150 ng/mL (375 nmol/L) — usually only reached through very high-dose supplementation (generally above 10,000 IU per day for prolonged periods) or prescription-strength loading doses without monitoring — may warrant attention. Standard maintenance doses (400–2,000 IU/day) used by many adults are not generally associated with this concern in the literature. Studies indicate that values in the 60–100 ng/mL (150–250 nmol/L) range are not associated with this concern, but research also does not consistently show additional benefit over values within typical sufficiency ranges. Discuss any concerns with a qualified healthcare provider.

Related Health3 Resources